HC Wainwright Raises Earnings Estimates for TG Therapeutics

TG Therapeutics, Inc. (NASDAQ:TGTX) – Research analysts at HC Wainwright raised their FY2026 earnings per share estimates for TG Therapeutics in a research report issued to clients and investors on Thursday, February 26th. HC Wainwright analyst E. Bodnar now expects that the biopharmaceutical company will earn $1.30 per share for the year, up from their prior forecast of $1.28. The consensus estimate for TG Therapeutics’ current full-year earnings is $0.08 per share. HC Wainwright also issued estimates for TG Therapeutics’ FY2027 earnings at $1.95 EPS, FY2028 earnings at $2.46 EPS and FY2029 earnings at $3.07 EPS.

Several other brokerages have also recently issued reports on TGTX. The Goldman Sachs Group lifted their target price on TG Therapeutics from $37.00 to $39.00 and gave the company a “neutral” rating in a research report on Thursday, January 15th. Cantor Fitzgerald reiterated an “overweight” rating on shares of TG Therapeutics in a research report on Wednesday, January 14th. B. Riley Financial upgraded TG Therapeutics to a “strong-buy” rating in a research report on Tuesday, November 4th. Wall Street Zen lowered TG Therapeutics from a “buy” rating to a “hold” rating in a research note on Saturday, February 14th. Finally, JPMorgan Chase & Co. cut their price objective on TG Therapeutics from $49.00 to $46.00 and set an “overweight” rating for the company in a report on Monday, February 2nd. One research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $50.00.

TG Therapeutics Trading Down 2.6%

TGTX opened at $30.09 on Monday. TG Therapeutics has a fifty-two week low of $25.28 and a fifty-two week high of $46.48. The firm has a market capitalization of $4.78 billion, a PE ratio of 10.86 and a beta of 1.87. The company has a debt-to-equity ratio of 0.40, a current ratio of 3.82 and a quick ratio of 2.89. The company’s 50-day moving average is $29.85 and its 200 day moving average is $31.48.

TG Therapeutics (NASDAQ:TGTX) last announced its quarterly earnings results on Thursday, February 26th. The biopharmaceutical company reported $0.14 EPS for the quarter, missing analysts’ consensus estimates of $0.35 by ($0.21). TG Therapeutics had a net margin of 72.56% and a return on equity of 119.68%. The business had revenue of $192.57 million for the quarter, compared to the consensus estimate of $192.15 million. During the same quarter last year, the firm posted $0.15 EPS. The business’s revenue for the quarter was up 78.0% compared to the same quarter last year.

Hedge Funds Weigh In On TG Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of TGTX. Congress Asset Management Co. purchased a new position in TG Therapeutics in the fourth quarter worth about $57,307,000. Man Group plc lifted its stake in shares of TG Therapeutics by 621.5% in the 3rd quarter. Man Group plc now owns 1,008,462 shares of the biopharmaceutical company’s stock worth $36,431,000 after purchasing an additional 868,697 shares during the period. BNP Paribas Financial Markets lifted its stake in shares of TG Therapeutics by 856.6% in the 4th quarter. BNP Paribas Financial Markets now owns 683,653 shares of the biopharmaceutical company’s stock worth $20,380,000 after purchasing an additional 612,189 shares during the period. Goldman Sachs Group Inc. boosted its holdings in shares of TG Therapeutics by 35.0% in the fourth quarter. Goldman Sachs Group Inc. now owns 2,051,132 shares of the biopharmaceutical company’s stock worth $61,144,000 after buying an additional 531,759 shares during the last quarter. Finally, Invesco Ltd. grew its position in TG Therapeutics by 47.1% during the fourth quarter. Invesco Ltd. now owns 1,609,815 shares of the biopharmaceutical company’s stock valued at $47,989,000 after buying an additional 515,481 shares during the period. 58.58% of the stock is currently owned by hedge funds and other institutional investors.

More TG Therapeutics News

Here are the key news stories impacting TG Therapeutics this week:

• Positive Sentiment: Record BRIUMVI-driven revenue growth — Q4 total revenue rose ~78% y/y with U.S. BRIUMVI net revenue of $182.7M and full‑year 2025 BRIUMVI sales of ~$594M (≈+90% y/y); management raised BRIUMVI revenue guidance for 2026, underpinning top‑line momentum. TGTX Q4 Earnings Lag Estimates, Briumvi Sales Drive Top Line
• Positive Sentiment: Analyst model upgrades — HC Wainwright raised Q1–Q3 2026 and FY2030 EPS estimates, signaling growing sell‑side confidence in profitability as BRIUMVI scales. Upgrades can support the stock over the coming quarters. HC Wainwright raises estimates (MarketBeat)
• Positive Sentiment: Meaningful pipeline & commercialization catalysts — Investors highlight potential upside from the Phase 3 ENHANCE study (consolidated dosing) and development of a self‑administered subcutaneous BRIUMVI formulation, which could expand addressable market and margins if successful. TG Therapeutics: ‘Strong Buy’ On BRIUMVI’s Massive Growth
• Neutral Sentiment: Company reaffirmed 2026 revenue outlook and held a conference call outlining commercial execution and retention metrics — positive context, but near‑term stock reaction depends on reconciling EPS miss with guidance. TG Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results
• Negative Sentiment: Big EPS disappointment — Reported EPS of $0.14 vs. consensus ~$0.35 (≈-60% surprise); the profit miss is the main short‑term catalyst for the share decline despite strong revenues. TGTX Q4 Earnings Lag Estimates (Zacks)
• Negative Sentiment: Near-term volatility risk — Large EPS miss increases odds of short‑term selling pressure and gives traders a reason to pare back positions until subsequent quarters show margin improvement or clearer evidence that guidance will be achieved. TG Therapeutics (TGTX) Misses Q4 Earnings Estimates

About TG Therapeutics

TG Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in New York City that specializes in developing targeted therapies for hematological malignancies and autoimmune diseases. The company’s research strategy focuses on the modulation of B-cell biology through novel antibody and small‐molecule agents. Since its founding in 2003, TG Therapeutics has built a diversified portfolio aimed at addressing unmet medical needs in oncology and immunology.

In December 2022, TG Therapeutics achieved its first commercial milestone when ublituximab-xiiy (marketed as Briumvi® in collaboration with Biogen) received U.S.